About SPRIX
SPRIX is a company based in United States founded in 2003 was acquired by Egalet in January 2015. It operates as a Direct-to-Consumer (D2C). The company has 1,490 employees as of September 30, 2024. SPRIX offers products and services including SPRIX Nasal Spray.
- Headquarter United States
- Employees 1490 as on 30 Sep, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
- Legal Name Sprix Ltd.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of SPRIX
SPRIX is a publicly listed company on the TSE with ticker symbol 7030 in Japan, operating in the Consumer services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of SPRIX
SPRIX offers a comprehensive portfolio of products and services, including SPRIX Nasal Spray.
Used for short-term moderate to severe pain management.
Funding Insights of SPRIX
Detailed funding history for SPRIX
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in SPRIX
SPRIX has secured backing from 1 investor. Prominent investors backing the company include Egalet.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Therapeutics for pain management are developed with abuse-deterrent designs.
|
Locked | Locked | Locked |
Investor details for SPRIX
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SPRIX
Investment portfolio details for SPRIX
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SPRIX
Detailed financials for SPRIX
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Sprix Comparisons
Peer comparison for SPRIX
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SPRIX
Detailed competitors of SPRIX
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Sprix
Complete news archive for SPRIX
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SPRIX
SPRIX was founded in 2003.
SPRIX is headquartered in United States.
As of Sep 30, 2024, the latest employee count at SPRIX is 1,490.
Annual revenue of SPRIX is $237.37M as on Sep 30, 2025.
SPRIX, operated by Assertio Therapeutics, Inc., is engaged in the development and distribution of pharmaceutical products for pain management. The primary product, SPRIX Nasal Spray, is designed for short-term (up to 5 days) management of moderate to moderately severe pain in adult patients requiring opioid-level analgesia. Solutions are targeted at acute, post-surgical, and procedural pain across various medical contexts. The product is positioned as a non-narcotic alternative in the healthcare sector.
SPRIX offers SPRIX Nasal Spray.
Yes, SPRIX is publicly traded on TSE under the ticker symbol 7030.
SPRIX has 1 investor. Key investors include Egalet.
The ticker symbol of SPRIX is 7030 on TSE.